Researchers develop quantum dot smartphone device to diagnose and track COVID-19 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Originally Published July 2000 INDUSTRY NEWS Device Applications Drive Innovations in Display Technology Rexam Restructures, Invests in New Equipment Magnetic
Pfizer COVID-19 vaccine trials in children promising , but expert urges patience
Last Updated Mar 31, 2021 at 7:10 am PDT
In this Dec. 22, 2020, photo, provided by Richard Chung, his son Caleb Chung receives the first dose of Pfizer coronavirus vaccine or placebo as a trial participant for kids ages 12-15, at Duke University Health System in Durham, N.C. Pfizer says its COVID-19 vaccine is safe and strongly protective in kids as young as 12. The announcement Wednesday, March 31, 2021 marks a step toward possibly beginning shots in this age group before the next school year. (Richard Chung via AP)
Summary
Pfizer says early trial data shows its COVID-19 vaccine has so far been effective in kids aged 12 to 15
UTC
U of T Entrepreneurship Week: Six startups working on COVID-19 innovations U of T startup Structura Biotechnology, headed by Saara Virani and Ali Punjani, helped U.S. researchers produce an atomic scale map of the spike on SARS-CoV-2 by using the startup s AI technology (photo by Chris Sorensen)
From speeding up diagnostic testing to streamlining communications between health-care facilities and promoting hand-washing, University of Toronto startups are finding a number of ways to contribute to the fight against COVID-19.
Many U of T entrepreneurs pivoted quickly during the early days of the pandemic to help address a global health threat, demonstrating a capacity for innovation, flexibility and quick-thinking.
NHRI in talks to make material for anti-obesity drugs
Staff writer, with CNA
The National Health Research Institutes (NHRI) are in talks with Taiwanese companies to produce a unique nanomaterial found to reduce the side effects of obesity treatment drugs, an NHRI researcher said yesterday.
Lo Leu-wei (羅履維), an Institute of Biomedical Engineering and Nanomedicine researcher, said that his team has developed a unique nanomaterial using mesoporous silica nanoparticles (MSNs) to reduce the side effects of lipase inhibitor-based obesity treatment medications.
The NHRI is in talks with three Taiwanese firms to mass produce MSNs, he said.
A research team from the National Health Research Institutes’ Institute of Biomedical Engineering and Nanomedicine, led by researcher Lo Leu-wei, right, present the findings of a study on the side effects of anti-obesity drugs at a news conference in Taipei yesterday.